|
|
[Report]
ANGIOGENESIS MODULATORS - A MARKET INSIGHT REPORT
Published: 2008/01
|
|
 |
|
|
|
Table of Contents
I. SCOPE AND METHODOLOGY
II. REPORT SYNOPSIS
1. Introduction
- Angiogenesis
- Segmentation of Angiogenesis
- Exhibit 1: Segmentation of Global Angiogenesis Therapeutic Products
Market by Angiogenesis Modulators (Inhibitors and Stimulators) and
Therapeutic Areas (Cancer, Cardiovascular and Other)
2. Global Market Analysis
- Exhibit 2: Angiogenesis Therapeutic Products (2005-2012) - Global Market
Analysis (Current & Future) in US$ Million (Graphical Representation Included)
3. Angiogenesis Modulators Analysis by Geographic Region
- Inhibitors
- Exhibit 3: Angiogenesis Inhibitors (2005-2012) - Global Market Analysis
(Current & Future) by Geographic Region for United States, Europe,
Asia-Pacific and Rest of World in US$ Million (Graphical Representation
Included)
- Exhibit 4: Angiogenesis Inhibitors (2006, 2009 and 2012) - Percentage
Breakdown of Global Market Value by Geographic Region for United States,
Europe, Asia-Pacific and Rest of World (Graphical Representation Included)
- Exhibit 5: Angiogenesis Inhibitors (2005-2012) - Global Analysis
(Current & Future) of Patients Treated by Geographic Region for United
States, Europe, Asis-Pacific and Rest of World in Million (Graphical
Representation Included)
- Exhibit 6: Angiogenesis Inhibitors (2006, 2009 and 2012) - Percentage
Breakdown of Patients Treated Globally by Geographic Region for United
States, Europe, Asia-Pacific and Rest of World (Graphical Representation
Included)
- Stimulators
- Exhibit 7: Angiogenesis Stimulators (2005-2012) - Global Market Analysis
(Current & Future) by Geographic Region for United States, Europe,
Asia-Pacific and Rest of World in US$ Million (Graphical Representation
Included)
- Exhibit 8: Angiogenesis Stimulators (2006, 2009 and 2012) - Percentage
Breakdown of Global Market Value by Geographic Region for United States,
Europe, Asia-Pacific and Rest of World
- Analysis of Angiogenesis Disease Area by Geographic Region
- Cancer
- Exhibit 9: Angiogenesis Therapeutic Products for Cancer (2005-2012)
- Global Market Analysis (Current & Future) by Geographic Region for
United States, Europe, Asia-Pacific and Rest of World in US$ Million
- Exhibit 10: Angiogenesis Therapeutic Products for Cancer (2006, 2009
and 2012) - Percentage Breakdown of Global Market Value by Geographic
Region for United States, Europe, Asia-Pacific and Rest of World
- Cardiovascular
- Exhibit 11: Angiogenesis Therapeutic Products for Cardiovascular
Diseases (2005-2012) - Global Market Analysis (Current & Future) by
Geographic Region for United States, Europe, Asia-Pacific and Rest of
World in US$ Million
- Exhibit 12: Angiogenesis Therapeutic Products for Cardiovascular
Diseases (2006, 2009 and 2012) - Percentage Breakdown of Global Market
Value by Geographic Region for United States, Europe, Asia-Pacific and
Rest of World
- Other
- Exhibit 13: Angiogenesis Therapeutic Products for Other Angiogenesis
Based Diseases (2005-2012) - Global Market Analysis (Current & Future)
by Geographic Region for United States, Europe, Asia-Pacific and Rest of
World in US$ Million (Graphical Representation Included)
- Exhibit 14: Angiogenesis Therapeutic Products for Other Angiogenesis
Based Diseases (2006, 2009 and 2012) - Percentage Breakdown of Global
Market Value by Geographic Region for United States, Europe,
Asia-Pacific and Rest of World
- Exhibit 15: List of Major Global Companies
4. Regional Market Analysis
- The United States
- Exhibit 16: Angiogenesis Therapeutic Products (2005-2012) - United
States Market Analysis (Current & Future) in US$ Million (Graphical
Representation Included)
- Major Companies in the United States
- Abbott Laboratories
- Adnexus Therapeutics, Inc.
- Alcon, Inc.
- Amgen, Inc.
- Ångstrom Pharmaceuticals, Inc
- Callisto Pharmaceuticals, Inc.
- Cardium Therapeutics, Inc.
- Celgene Corporation
- Collagenex Pharmaceuticals, Inc
- Eisai, Inc.
- Entremed, Inc.
- Genaera Corporation
- Genentech, Inc.
- Genvec, Inc.
- Genzyme Corporation
- Human Genome Sciences, Inc.
- Imclone Systems, Inc.
- Intradigm Corporation
- Merck & Co., Inc. (USA)
- OSI Pharmaceuticals, Inc.
- Oxigene, Inc
- Pfizer, Inc.
- The US Market Analysis by Type of Angiogenesis Modulators
- Exhibit 17: Angiogenesis Therapeutic Products (2005-2012) - United
States Market Analysis (Current & Future) by Angiogenesis Modulators for
Inhibitors and Stimulators in US$ Million (Graphical Representation
Included)
- Exhibit 18: Angiogenesis Therapeutic Products (2006, 2009 and 2012)
- Percentage Breakdown of United States Market Value by Angiogenesis
Modulators for Inhibitors and Stimulators (Graphical Representation
Included)
- Europe
- Exhibit 19: Angiogenesis Therapeutic Products (2005-2012) - European
Analysis (Current & Future) in US$ Million (Graphical Representation
Included)
- Major Companies in Europe
- Antisoma plc (UK)
- Astrazeneca plc (UK)
- Bayer Healthcare AG (Germany)
- F.Hoffmann-La Roche Ltd. (Switzerland)
- Merck KGaA(Germany)
- Novartis AG (Switzerland)
- UCB SA (Belgium)
- Angiogenesis Modulators Analysis by Geographic Region
- Inhibitors
- Exhibit 20: Angiogenesis Inhibitors (2005-2012) - European
Market Analysis (Current & Future) by Geographic Region for Germany,
United Kingdom, France, Switzerland and Rest of Europe in US$
Million (Graphical Representation Included)
- Exhibit 21: Angiogenesis Inhibitors (2006, 2009 and 2012) -
Percentage Breakdown of European Market Value by Geographic Region
for Germany, United Kingdom, France, Switzerland and Rest of Europe
(Graphical Representation Included)
- Stimulators
- Exhibit 22: Angiogenesis Stimulators (2005-2012) - European
Market Analysis (Current & Future) by Geographic Region for Germany,
United Kingdom, France, Switzerland and Rest of Europe in US$
Million (Graphical Representation Included)
- Exhibit 23: Angiogenesis Stimulators (2006, 2009 and 2012) -
Percentage Breakdown of European Market Value by Geographic Region
for Germany, United Kingdom, France, Switzerland and Rest of Europe
- Asia-Pacific
- Exhibit 24: Angiogenesis Therapeutic Products (2005-2012) -
Asia-Pacific Market Analysis (Current & Future) in US$ Million (Graphical
Representation Included)
- Major Companies in Asia-Pacific
- Bionomics Ltd. (Australia)
- Chugai Pharmaceutical Co., Ltd. (Japan)
- Progen Industries Ltd. (Australia)
- Angiogenesis Modulators Analysis by Geographic Region
- Inhibitors
- Exhibit 25: Angiogenesis Inhibitors (2005-2012) - Asia-Pacific
Market Analysis (Current & Future) by Geographic Region for Japan and
Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
- Exhibit 26: Angiogenesis Inhibitors (2006, 2009 and 2012) -
Percentage Breakdown of Asia-Pacific Market Value by Geographic Region
for Japan and Rest of Asia-Pacific (Graphical Representation Included)
- Stimulators
- Exhibit 27: Angiogenesis Stimulators (2005-2012) - Asia-Pacific
Market Analysis (Current & Future) by Geographic Region for Japan and
Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
- Exhibit 28: Angiogenesis Stimulators (2006, 2009 and 2012) -
Percentage Breakdown of Asia-Pacific Market Value by Geographic Region
for Japan and Rest of Asia-Pacific (Graphical Representation Included)
- Rest of World
- Exhibit 29: Angiogenesis Therapeutic Products (2005-2012) - Rest of
World Market Analysis (Current & Future) in US$ Million (Graphical
Representation Included)
- Angiogenesis Modulators Analysis by Geographic Region
- Inhibitors
- Exhibit 30: Angiogenesis Inhibitors (2005-2012) - Rest of World
Market Analysis (Current & Future) by Geographic Region for Latin
America and Other in US$ Million (Graphical Representation Included)
- Exhibit 31: Angiogenesis Inhibitors (2006, 2009 and 2012) -
Percentage Breakdown of Rest of World Market Value by Geographic
Region for Latin America and Other (Graphical Representation Included)
- Stimulators
- Exhibit 32: Angiogenesis Stimulators (2005-2012) - Rest of World
Market Analysis (Current & Future) by Geographic Region for Latin
America and Other in US$ Million (Graphical Representation Included)
- Exhibit 33: Angiogenesis Stimulators (2006, 2009 and 2012) -
Percentage Breakdown of Rest of World Market Value by Geographic
Region for Latin America and Other (Graphical Representation Included)
III. PRODUCT RESEARCH
1. Introduction
- Angiogenesis - The Growth of New Blood Vessels
- Global Growth Trends - Angiogenesis Therapeutic Products
- Exhibit 34: Global Market for Angiogenesis Therapeutic Products:
Geographic Regions (Asia-Pacific, United States and Europe) Ranked by
Projected CAGR for 2005 through 2012 (Graphical Representation Included)
- The Process
- The Types
- Sprouting Angiogenesis
- Role of Angioprotien in Sprouting of Angiogenesis
- Intussusceptive Angiogenesis
- Role of Intussusceptive Angiogenesis in Embryonic Vascular Network
Configuration
- Therapeutic Angiogenesis
- Role of Therapeutic Angiogenesis in Various Diseases
- Delivery of Drugs in Cancer Therapy through Angiogenesis
- Angiogenic Therapy for Heart?
2. Modulators of Angiogenesis
- Growth Trends - Global Angiogenesis Therapeutic Products by Modulators
- Exhibit 35: Global Market for Angiogenesis Therapeutic Products:
Angiogenesis Modulators (Stimulators and Inhibitors) Ranked by Projected
CAGR for 2005 through 2012 (Graphical Representation Included)
- 2.1 Angiogenesis Inhibitors
- Growth Trends - Global Market for Angiogenesis Inhibitors
- Exhibit 36: Global Market for Angiogenesis Inhibitors: Geographic
Regions (Asia-Pacific, United States, Europe ) Ranked by Projected CAGR
for 2005 through 2012 (Graphical Representation Included)
- Natural Angiogenesis Inhibitors
- Angiostatin - A Potent Angiogenesis Inhibitor of Tumor Growth
- Heparin Hexasaccharide Fragment
- Interleukin-12
- Placental Ribonuclease Inhibitor
- Retinoids
- Thrombospondin-1 (TSP-1)
- Role of TSP-1 as Autocrine Negative Regulator for Human Dendritic
Cell Activation
- Cartilage Derived Inhibitor
- Angioarrestin
- Endostatin
- Platelet Factor-4
- Metalloproteinase Inhibitors
- Interferon Alpha/Beta/Gamma
- Other
- 2.2 Angiogenesis Stimulators
- Growth Trends - Global Market for Angiogenesis Stimulators
- Exhibit 37: Global Market for Angiogenesis Stimulators: Geographic
Regions (Asia-Pacific, United States and Europe) Ranked by Projected CAGR
for 2005 through 2012 (Graphical Representation Included)
- Natural Angiogenic Stimulators
- Vascular Endothelial Growth Factor
- VEGF Splice Variants and Their Functions
- Role of VEGF in Various Diseases
- Effect of VEGF & bFGF on In-vivo and In-vitro Conditions
- Fibroblast Growth Factors
- Basic FGF
- Expression of bFGF (FGF2) in Various Diseases
- Alzheimer' s
- Precursor Neural Cells of Mice
- Acidic FGF
- Role of aFGF in ADPKD
- Expression of aFGF in Alzheimer' s
- Granulocyte Colony-Stimulating Factor
- Impact of G-CSF on Neutrophils
- The Usage of G-CSF in Pharma Industry
- Angiogenin
- Angiopoietin-1
- Platelet Derived Endothelial Cell Growth Factor
- Uterine Cervical Cancers and Role of PD-ECGF
- Leptin
- Midkine
- Placental Growth Factor
- Stimulation of Inflammation and Swelling - A Role of Placental
Growth Factor
- Hepatocyte Growth Factor (HGF)/Scatter Factor (SF)
- Transforming Growth Factor (TGF)
- Other
3. Angiogenesis in Diseases
- Growth Trends - Global Market for Angiogenesis Therapeutic Areas
- Exhibit 38: Global Market for Angiogenesis Therapeutic Products: Major
Angiogenesis Therapeutic Areas (Cardiovascular Disorders, Other* and Cancer)
Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation
Included)
- 3.1 Remedy of Diseases with Angiogenesis Inhibitors
- Angiogenesis Inhibitors-Patient Demographics
- Exhibit 39: Angiogenesis Inhibitors (2005-2011): Global Analysis
(Current & Future) of Patients Treated in Million
- Cancer Therapy - Role of Angiogenesis
- Global Market for Major Cancer Types
- Exhibit 40: Major Cancer Types (2005 & 2006): Global Market for Major
Cancer Types - Breast, Colorectal, Lung and Prostate in US$ Million
(Graphical Representation Included)
- Growth Trends - Global Market for Angiogenesis Therapeutic Products for
Cancer
- Exhibit 41: Global Market for Angiogenesis Therapeutic Products for
Cancer: Geographic Regions (Asia-Pacific, United States and Europe) Ranked
by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
- Cancer Therapy Angiogenesis Vs Conventional
- Conventional Cancer Treatments
- Surgery
- Radiation Therapy for Healing Cancer
- Chemotherapy Treatment
- Hormone Stimulation Therapy
- Process of Immuno Therapy
- Experimenting Phase
- Targeted Therapy
- Angiostatic Therapy
- Angiostatic Agents
- Angiolytic Photodynamic Therapy
- Researches in Development of Cancer Therapy
- Angiobalans
- Global Cancer Demographics
- Exhibit 42: Cancer Incidents (2006, 2011 & 2020): Estimates and
Projections for Global Cancer Incidents in Million/Year with Mortality
Percentage (Graphical Representation Included)
- Alzheimer' s
- Dermatology
- Cosmetic Dermatology
- Angiogenesis in Dermatology
- Angiogenesis Inhibitor
- Angiogenesis Stimulating Drugs
- Psoriasis
- Role of Angiogenesis in Psoriasis
- Rosacea
- MoA of Photoaging in Rosacea Pathogenesis
- Ophthalmology
- Age Related Macular Degeneration
- Advanced stage of vision loss
- Causes
- Characteristics of the disorder
- Detection process of the Disorder
- Medication
- Precautionary measure
- Types of AMD
- Non-Neo-vascular (dry) AMD
- Neo-vascular (wet) AMD
- Other Turmoil Based on Angiogenesis
- Rubeosis Iridis
- Neovascularization
- Neovascularization in Association with Angiogenesis
- Rheumatology
- Rheumatoid Arthritis
- Angiogenesis in Rheumatoid Arthritis - Pathogenic and Therapeutic
Implications
- Skin Related Ailments
- Deficient Angiogenesis in Skin Diseases
- Osteoarthritis (OA), Angiogenesis and Inflammation
- Other
- Inflammatory Diseases
- Growth of New Blood Vessels in Inflammation
- Cause of joint swelling due to inflammation
- Endometriosis
- 3.2 Remedy of Diseases with Angiogenesis Stimulators
- Wound Care - Role of Angiogenesis
- Soluble Factors Responsible for Wound Angiogenesis
- Diabetic Foot Ulcers
- Angiogenesis in Cardiovascular Disorders
- Growth Trends - Global Market for Angiogenesis Therapeutic Products
for Cardiovascular Disorders
- Exhibit 43: Global Market for Angiogenesis Therapeutic Products for
Cardiovascular Disorders: Geographic Regions (United States,
Asia-Pacific and Europe) Ranked by Projected CAGR for 2005 through 2012
(Graphical Representation Included)
- Ischemia
- Role of ASK 1 in Angiogenesis during Ischemia
- Role of NGF in Neo-Vascularization during Ischemic Conditions
- Congestive Heart Failure
- Root of CHF
- Detection of CHF
- Treatment of CHF
- Role of Angiogenesis in CHF
- Coronary Artery Disease
- Angina
- Heart Attack
- Heart Failures
- Arrhythmias
- Symptoms Identified for CAD
- Role of Angiogenesis in CAD Treatment
- Peripheral Vascular Disease
- Angiogenic Therapy for the Treatment of PVD
- Peripheral Artery Disease
- Therapeutic Angiogenesis in PAD
- Myocardial Infarction
- Treatment of Myocardial Infarction Using Non-Invasive Imaging of
Myocardial Angiogenesis
IV. MARKET DYNAMICS
1. Market Overview
- Global Market Analysis
- Exhibit 44 Angiogenesis Therapeutic Products (2005-2012) - Global Market
Analysis (Current & Future) by Geographic Region for United States, Europe,
Asia-Pacific and Rest of World in US$ Million (Graphical Representation
Included)
- Exhibit 45 Angiogenesis Therapeutic Products (2006, 2009 and 2012) -
Percentage Breakdown of Global Market Value by Geographic Region for United
States, Europe, Asia-Pacific and Rest of World (Graphical Representation
Included)
2. Major Companies in Angiogenesis Industry
- Abbott Laboratories (USA)
- Adnexus Therapeutics, Inc. (USA)
- Aeterna Zentaris, Inc. (Canada)
- Alcon, Inc. (USA)
- Amgen, Inc. (USA)
- Angiotech Pharmaceuticals, Inc. (Canada)
- Ångstrom Pharmaceuticals, Inc. (USA)
- Antisoma plc (UK)
- Astrazeneca plc (UK)
- Bayer Healthcare AG (Germany)
- Callisto Pharmaceuticals, Inc. (USA)
- Cardium Therapeutics, Inc. (USA)
- Celgene Corporation (USA)
- Chugai Pharmaceutical Co., Ltd. (Japan)
- Collagenex Pharmaceuticals, Inc. (USA)
- Eisai, Inc. (USA)
- Entremed, Inc. (USA)
- F.Hoffmann-La Roche Ltd. (Switzerland)
- Genaera Corporation (USA)
- Genentech, Inc. (USA)
- Genvec, Inc. (USA)
- Genzyme Corporation (USA)
- Human Genome Sciences, Inc. (USA)
- Imclone Systems, Inc. (USA)
- Intradigm Corporation (USA)
- Merck & Co., Inc. (USA)
- Merck KGaA (Germany)
- Novartis AG (Switzerland)
- OSI Pharmaceuticals, Inc. (USA)
- Oxigene, Inc. (USA)
- Pfizer, Inc. (USA)
- Progen Industries Ltd. (Australia)
- TAP Pharmaceutical Products, Inc. (USA)
- UCB SA (Belgium)
3. Major Activities in Angiogenesis Industry
- Nexavar® First FDA-Approved Drug Therapy for Liver Cancer
- Bionomics' Anti-Cancer Compound Gains IND Approval
- Bilateral Agreement for Product Distribution between Cell Culture Service
and TCS Cellworks Limited
- Coley Agrees to Acquisition by Pfizer
- Chugai Achieves Japanese Regulatory Approval for Tarceva® for NSCLC
Treatment
- Synta Pharmaceuticals and GSK to Jointly Develop STA-4783
- Atrium Biotechnologies Inc. will Become Atrium Innovations, Inc.
- ARIAD Announces Collaboration with ICON Medical to Develop and
Commercialize Novel Deforolimus-Eluting Stents
- Bristol-Myers Squibb Acquires Adnexus Therapeutics
- Celera Enters Oncology Research Collaboration with Merck to Develop
PharmacogenomicTests Avastin® and Chemotherapy Combination as First-line
Treatment for NSCLC Approved in Europe
- Genentech Acquires Tanox
- System Medicine, Now a Wholly Owned Subsidiary of Cell Therapeutics, Inc
- ARIAD and Merck & Co., Inc. Announce Global Collaboration to Jointly
Develop and Commercialize AP23573 - ARIAD' s Novel mTOR Inhibitor - for Cancer
- Valentis and Urigen Merge
- National Cancer Institute Selects SR 16388 of SRI International
- Abbott and Genentech Announce Global, Integrated Research, Development and
Commercialization Collaboration in Oncology
- Strategic Alliance Between Merck and Archemix
- Progen Industries is Now Progen Pharmaceuticals
- Chugai Pharmaceutical Obtains Approval for Avastin® in Japan
- Eisai Corporation Concludes the Deal to Acquire Morphotek, Inc.
- Celera and LabCorp® Announce Licensing Agreement to Commercialize
Breast Cancer Testing Assays
- Paradigm Therapeutics Acquired by Takeda Pharmaceutical
- ARIAD Grants Second Commercial License to its Patented ARGENT(TM)
Cell-Signaling Regulation Technology for Development of New Cancer Therapies
- University of Bristol Awards Drug Discovery Contract to Galapagos NV
- ImClone Systems Decides to Focus on its Proprietary Product, IMC-1121B
- AngioGenetics Discovers New Mechanism for Blood Vessel Growth
- Seattle Genetics in Exclusive Worldwide Licensing Agreement with Genentech
for SGN-40
- Celgene Acquires API Unit from Siegfried Ltd.
- Otsuka and Chugai in Co-Promotion Deal
- Merck Buys Entire Stake in Sirna Therapeutics
- Genetix Acquires Applied Imaging Corporation
- InterMune and Roche Close Collaboration Agreement
- EntreMed Presents 2ME2 for Rheumatoid Arthritis
- Genzyme Acquires AnorMed
- Biomira Acquires ProlX Pharmaceuticals
- Pfizer Acquires PowderMed
- CTT Cancer Targeting Technologies and Karyon Ltd., Merge
- LibraGen and Sanofi-Aventis in Partnership for Microbial Diversity
Applications
- Schering and Sonus Sign Global Licensing Agreement for TOCOSOL(R)
Paclitaxel
- Merck Acquires Serono
- Sangamo Acquires Edwards' Angiogenesis Program
- AstraZeneca Acquires Cambridge Antibody Technology
- GSK and Shionogi Complete Initial Clinical Study for HIV Integrase
Inhibitor
- Cardium Acquires Wound Healing Technology and Related Assets of TRC
- GSK and Galapagos Enter Into an Alliance for Osteoarthritis Drug
Development
- Caliper Acquires Xenogen
- Pharmacopeia and Allergan Inc., in AMD Research Agreement
- Angiotech Pharmaceuticals Acquires Quill Medical Inc.
- Mayne Acquires SuperGen' s North American Rights for Oncology Products
- Erbitux ® Approved in the US
- Corgentech Adopts New Name
- Angiotech and Genzyme Enter Into Strategic Collaboration for Developing
Oncology Treatments
- Alcon and Amgen for Joint Development of Ophthalmology Therapies
- CancerVax Merges with Micromet
- Microbix and Angiogen Enter Into Marketing Agreement
- SuperGen Acquires Montigen
- Novartis Takes Over Chiron
- Amgen Completes Acquisition of Abgenix
- AEterna Zentaris' Development of Cetrorelix to Continue In Japan
- Corautus Genetics Puts Forth VEGF-2 Studies
- Angiotech Pharmaceuticals Takes Over American Medical Instruments
- Amgen and Biovitrum in License Agreement
- Cryptome Takes Over HealthLinx
- AngioGenex Merges with eClic
- Merck Acquires Full US Rights to BLP25 Liposome Vaccine from Biomira
- Human Genome Science and Amgen in Licensing Agreement
- Protein Design Labs Changes Corporate Identity
- Bausch & Lomb and PTC Therapeutics in Research Collaboration Deal
- Sanofi-Aventis and Regeneron Pharmaceuticals Amend VEGF Collaboration
- OSI Pharmaceuticals Acquires Eyetech Pharmaceuticals
- Hybridon Adopts New Name
- Xencor and Centocor Enter into Monoclonal Antibodies Agreement
- Corautus in Diabetic Neuropathy Licensing Agreement
- Xantos and Cryptome Sign Agreement to Validate Cancer Leads
- Xantos and Atugen Sign Collaboration Agreement
- Allergan and Sanwa Kagaku Kenkyusho Develop Posurdex in Japan
- Corautus and Boehringer Ingelheim Sign Agreement to Produce VEGF-2
- Bayer and Onyx Announce Access to Sorafenib (BAY 43-9006)
- 7TM Signs Therapeutic Angiogenesis Research Agreement with P&G
- Genzyme Acquires Verigen
- Antisoma and Raylo Sign Agreement for Manufacturing AS1411
- Alcon and Morphochem Enter Into Alliance for Ophthalmic Compounds
- ImClone Systems Signs License Agreements
- Pfizer Takes Over Angiosyn
4. Regional Market Analysis
- A. The United States
- Market Analysis
- Cancer Incidents in the United States
- Exhibit 46: Cancer Incidents and Percentage of Deaths in the United
States in 2005 and 2006
- Exhibit 47: US Cancer Incidents (2006): No. of Cases by Type of
Cancer - Prostate, Breast, Lung, Colorectal and Other (Graphical
Representation Included)
- US Market for Interventional Peripheral Vascular Products
- Exhibit 48: Interventional Peripheral Vascular Products (2004 &
2009) - The US Market Analysis in US$ Million
- Analysis by Type of Angiogenesis Modulators
- Exhibit 49: Angiogenesis Therapeutic Products (2005-2012) - United
States Market Analysis (Current & Future) by Angiogenesis Modulators for
Inhibitors and Stimulators in US$ Million (Graphical Representation
Included)
- Exhibit 50: Angiogenesis Therapeutic Products (2006, 2009 and 2012)
- Percentage Breakdown of United States Market Value by Angiogenesis
Modulators for Inhibitors and Stimulators (Graphical Representation
Included)
- Analysis by Disease Area
- Exhibit 51: Angiogenesis Therapeutic Products (2005-2012) - United
States Market Analysis (Current & Future) by Disease Area for Cancer,
Cardiovascular and Other in US$ Million (Graphical Representation
Included)
- Exhibit 52: Angiogenesis Therapeutic Products (2006, 2009 and 2012)
- Percentage Breakdown of United States Market Value by Disease Area for
Cancer, Cardiovascular and Other
- Exhibit 53: List of Major Companies in the United States
- B. Europe
- Market Analysis
- Exhibit 54: Angiogenesis Therapeutic Products (2005-2012) - European
Market Analysis (Current & Future) in US$ Million (Graphical
Representation Included)
- Analysis by Geographic Region
- Exhibit 55: Angiogenesis Therapeutic Products (2005-2012) - European
Market Analysis (Current & Future) by Geographic Region for Germany,
United Kingdom, France, Switzerland, and Rest of Europe in US$ Million
(Graphical Representation Included)
- Exhibit 56: Angiogenesis Therapeutic Products (2006, 2009 and 2012) -
Percentage Breakdown of European Market Value by Geographic Region for
Germany, United Kingdom, France Switzerland, and Rest of Europe
- Analysis by Type of Angiogenesis Modulators
- Exhibit 57: Angiogenesis Therapeutic Products (2005-2012) - European
Market Analysis (Current & Future) by Angiogenesis Modulators for
Inhibitors and Stimulators in US$ Million (Graphical Representation
Included)
- Exhibit 58: Angiogenesis Therapeutic Products (2006, 2009 and 2012) -
Percentage Breakdown of European Market Value by Angiogenesis Modulators
for Inhibitors and Stimulators (Graphical Representation Included)
- Analysis by Disease Area
- Exhibit 59: Angiogenesis Therapeutic Products (2005-2012) - European
Market Analysis (Current & Future) by Disease Area for Cancer,
Cardiovascular and Other in US$ Million (Graphical Representation Included)
- Exhibit 60: Angiogenesis Therapeutic Products (2006, 2009 and 2012) -
Percentage Breakdown of European Market Value by Disease Area for Cancer,
Cardiovascular and Other
- Exhibit 61 List of Major Companies in Europe
- European Angiogenesis Modulators Market by Country
- B1. Germany
- German Market Analysis
- Analysis by Type of Angiogenesis Modulators
- Exhibit 62: Angiogenesis Therapeutic Products (2005-2012) - German
Market Analysis (Current & Future) by Angiogenesis Modulators for
Inhibitors and Stimulators in US$ Million (Graphical Representation
Included)
- Exhibit 63: Angiogenesis Therapeutic Products (2006, 2009 and 2012) -
Percentage Breakdown of German Market Value by Angiogenesis Modulators for
Inhibitors and Stimulators (Graphical Representation Included)
- B2. The United Kingdom
- UK Market Analysis
- Analysis by Type of Angiogenesis Modulators
- Exhibit 64: Angiogenesis Therapeutic Products (2005-2012) - United
Kingdom Market Analysis (Current & Future) by Angiogenesis Modulators for
Inhibitors and Stimulators in US$ Million (Graphical Representation
Included)
- Exhibit 65: Angiogenesis Therapeutic Products (2006, 2009 and 2012) -
Percentage Breakdown of United Kingdom Market Value by Angiogenesis
Modulators for Inhibitors and Stimulators (Graphical Representation
Included)
- B3. France
- French Market Analysis
- Analysis by Type of Angiogenesis Modulators
- Exhibit 66: Angiogenesis Therapeutic Products (2005-2012) - French
Market Analysis (Current & Future) by Angiogenesis Modulators for
Inhibitors and Stimulators in US$ Million (Graphical Representation
Included)
- Exhibit 67: Angiogenesis Therapeutic Products (2006, 2009 and 2012) -
Percentage Breakdown of French Market Value by Angiogenesis Modulators for
Inhibitors and Stimulators (Graphical Representation Included)
- B4. Switzerland
- Swiss Market Analysis
- Analysis by Type of Angiogenesis Modulators
- Exhibit 68: Angiogenesis Therapeutic Products (2005-2012) - Swiss
Market Analysis (Current & Future) by Angiogenesis Modulators for
Inhibitors and Stimulators in US$ Million (Graphical Representation
Included)
- Exhibit 69: Angiogenesis Therapeutic Products (2006, 2009 and 2012) -
Percentage Breakdown of Swiss Market Value by Angiogenesis Modulators for
Inhibitors and Stimulators (Graphical Representation Included)
- B5. Rest of Europe
- Rest of Europe Market Analysis
- Analysis by Type of Angiogenesis Modulators
- Exhibit 70: Angiogenesis Therapeutic Products (2005-2012) - Rest of
Europe Market Analysis (Current & Future) by Angiogenesis Modulators for
Inhibitors and Stimulators in US$ Million (Graphical Representation
Included)
- Exhibit 71: Angiogenesis Therapeutic Products (2006, 2009 and 2012) -
Percentage Breakdown of Rest of Europe Market Value by Angiogenesis
Modulators for Inhibitors and Stimulators (Graphical Representation
Included)
- C. Asia-Pacific
- Market Analysis
- Exhibit 72: Angiogenesis Therapeutic Products (2005-2012) -
Asia-Pacific Market Analysis (Current & Future) in US$ Million (Graphical
Representation Included)
- Analysis by Geographic Region
- Exhibit 73: Angiogenesis Therapeutic Products (2005-2012) -
Asia-Pacific Market Analysis (Current & Future) by Geographic Region for
Japan and Rest of Asia-Pacific in US$ Million (Graphical Representation
Included)
- Exhibit 74: Angiogenesis Therapeutic Products (2006, 2009 and 2012) -
Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for
Japan and Rest of Asia-Pacific (Graphical Representation Included)
- Analysis by Angiogenesis Modulators
- Exhibit 75: Angiogenesis Therapeutic Products (2005-2012) -
Asia-Pacific Market Analysis (Current & Future) by Angiogenesis Modulators
for Inhibitors and Stimulators in US$ Million (Graphical Representation
Included)
- Exhibit 76: Angiogenesis Therapeutic Products (2006, 2009 and 2012) -
Percentage Breakdown of Asia-Pacific Market Value by Angiogenesis
Modulators for Inhibitors and Stimulators (Graphical Representation
Included)
- Analysis by Disease Area
- Exhibit 77: Angiogenesis Therapeutic Products (2005-2012) -
Asia-Pacific Market Analysis (Current & Future) by Disease Area for
Cancer, Cardiovascular and Other in US$ Million (Graphical Representation
Included)
- Exhibit 78: Angiogenesis Therapeutic Products (2006, 2009 and 2012) -
Percentage Breakdown of Asia-Pacific Market Value by Disease Area for
Cancer, Cardiovascular and Other
- Exhibit 79: List of Major Companies in Asia-Pacific
- Asia-Pacific Angiogenesis Modulators Market by Country
- C1. Japan
- Japanese Market Analysis
- Analysis by Angiogenesis Modulators
- Exhibit 80: Angiogenesis Therapeutic Products (2005-2012) - Japanese
Market Analysis (Current & Future) by Angiogenesis Modulators for
Inhibitors and Stimulators in US$ Million (Graphical Representation
Included)
- Exhibit 81: Angiogenesis Therapeutic Products (2006, 2009 and 2012)
- Percentage Breakdown of Japanese Market Value by Angiogenesis
Modulators for Inhibitors and Stimulators (Graphical Representation
Included)
- C2. Rest of Asia-Pacific
- Rest of Asia-Pacific Market Analysis
- Analysis by Type of Angiogenesis Modulators
- Exhibit 82: Angiogenesis Therapeutic Products (2005-2012) - Rest of
Asia-Pacific Market Analysis (Current & Future) by Angiogenesis
Modulators for Inhibitors and Stimulators in US$ Million (Graphical
Representation Included)
- Exhibit 83: Angiogenesis Therapeutic Products (2006, 2009 and 2012)
- Percentage Breakdown of Rest of Asia-Pacific Market Value by
Angiogenesis Modulators for Inhibitors and Stimulators (Graphical
Representation Included)
- D. Rest of World
- Market Analysis
- Exhibit 84: Angiogenesis Therapeutic Products (2005-2012) - Rest of
World Market Analysis (Current & Future) in US$ Million (Graphical
Representation Included)
- Analysis by Geographic Region
- Exhibit 85: Angiogenesis Therapeutic Products (2005-2012) - Rest of
World Market Analysis (Current & Future) by Geographic Region for Latin
America and Other in US$ Million (Graphical Representation Included)
- Exhibit 86: Angiogenesis Therapeutic Products (2006, 2009 and 2012) -
Percentage Breakdown of Rest of World Market Value by Geographic Region
for Latin America and Other (Graphical Representation Included)
- Analysis by Angiogenesis Modulators
- Exhibit 87: Angiogenesis Therapeutic Products (2005-2012) - Rest of
World Market Analysis (Current & Future) by Angiogenesis Modulators for
Inhibitors and Stimulators in US$ Million (Graphical Representation
Included)
- Exhibit 88: Angiogenesis Therapeutic Products (2006, 2009 and 2012) -
Percentage Breakdown of Rest of World Market Value by Angiogenesis
Modulators for Inhibitors and Stimulators (Graphical Representation
Included)
- Analysis by Disease Area
- Exhibit 89: Angiogenesis Therapeutic Products (2005-2012) - Rest of
World Market Analysis (Current & Future) by Disease Area for Cancer,
Cardiovascular and Other in US$ Million (Graphical Representation Included)
- Exhibit 90: Angiogenesis Therapeutic Products (2006, 2009 and 2012) -
Percentage Breakdown of Rest of World Market Value by Disease Area for
Cancer, Cardiovascular and Other
- Rest of World Angiogenesis Market by Region
- D1. Latin America
- Latin American Market Analysis
- Analysis by Angiogenesis Modulators
- Exhibit 91: Angiogenesis Therapeutic Products (2005-2012) - Latin
America Market Analysis (Current & Future) by Angiogenesis Modulators
for Inhibitors and Stimulators in US$ Million (Graphical Representation
Included)
- Exhibit 92: Angiogenesis Therapeutic Products (2006, 2009 and 2012)
- Percentage Breakdown of Latin America Market Value by Angiogenesis
Modulators for Inhibitors and Stimulators (Graphical Representation
Included)
- D2. Rest of World (Excluding Latin America)
- Other Region in Rest of World' s Market Analysis
- Analysis by Angiogenesis Modulators
- Exhibit 93: Angiogenesis Therapeutic Products (2005-2012) - Other
Region of Rest of World Market Analysis (Current & Future) by
Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million
(Graphical Representation Included)
- Exhibit 94: Angiogenesis Therapeutic Products (2006, 2009 and 2012)
- Percentage Breakdown of Other Region of Rest of World Market Value by
Angiogenesis Modulators for Inhibitors and Stimulators (Graphical
Representation Included)
- Exhibit 95: List of Major Companies in Rest of World (Excluding
Latin America)
5. Angiogenesis Modulators - The Industry Outlook
V. CORPORATE DIRECTORY
|
|
|
|
|
|
|
[Report]
ANGIOGENESIS MODULATORS - A MARKET INSIGHT REPORT
Published: 2008/01
|
Published by : RI Technologies  |
|
|
Price:
|
Product Code : RIT63061 |
|
|
Please inform me when related publications are released
|
|
|
View Cart
